PapersFlow Research Brief
Viral-associated cancers and disorders
Research Guide
What is Viral-associated cancers and disorders?
Viral-associated cancers and disorders are malignancies and related conditions caused by viral infections, particularly Epstein-Barr virus (EBV) and Kaposi's Sarcoma-associated herpesvirus (KSHV), that develop at higher rates in immunocompromised individuals such as those with HIV/AIDS or transplant recipients.
This field examines 64,855 papers on the incidence, risk factors, and management of cancers linked to viruses like EBV and KSHV in patients with immunosuppression. Key studies identify unique herpesvirus-like DNA sequences in over 90 percent of AIDS-associated Kaposi's sarcoma tissues (Chang et al., 1994). Research also covers viral sequences in AIDS-related body-cavity-based lymphomas and their distinction from other lymphoid neoplasms (Cesarman et al., 1995).
Topic Hierarchy
Research Sub-Topics
Post-Transplant Lymphoproliferative Disorder
This sub-topic examines the pathogenesis, risk factors, and clinical management of PTLD in transplant recipients, focusing on EBV reactivation under immunosuppression. Researchers study diagnostic criteria, prognostic markers, and outcomes of rituximab-based therapies.
EBV-Associated Lymphomas in HIV
This area investigates the epidemiology, molecular mechanisms, and therapeutic responses of EBV-driven lymphomas like Burkitt and primary CNS lymphoma in HIV/AIDS patients. Studies emphasize the role of immune reconstitution via ART in altering disease course.
KSHV-Associated Kaposi's Sarcoma Pathogenesis
Researchers explore viral oncogenes, host immune evasion, and cytokine dysregulation in KSHV-driven Kaposi's sarcoma, particularly in AIDS and transplant settings. Work includes animal models and molecular virology to identify therapeutic targets.
Viral Reactivation under Immunosuppression
This sub-topic covers mechanisms of EBV and KSHV latency disruption in immunosuppressed hosts, including T-cell dysfunction and pharmacologic triggers. Studies develop monitoring assays and prophylactic interventions to prevent oncogenesis.
Immune-Based Therapies for Viral Malignancies
Focuses on adoptive T-cell therapies, checkpoint inhibitors, and EBV-specific vaccines for treating KSHV/EBV cancers in immunocompromised patients. Clinical trials assess efficacy and toxicity in HIV and transplant cohorts.
Why It Matters
Viral-associated cancers impose a substantial global health burden, with infections accounting for a fraction of all cancers worldwide as estimated in 2002 (Parkin, 2006). In AIDS patients, KSHV DNA sequences appear in more than 90 percent of Kaposi's sarcoma tissues but not in non-AIDS tissues, linking the virus directly to this malignancy (Chang et al., 1994). Similarly, these sequences occur in AIDS-related body-cavity-based lymphomas, indicating a pathogenic role for the novel herpesvirus distinct from other B-cell lymphomas (Cesarman et al., 1995). The International Agency for Research on Cancer classified biological agents including these viruses as human carcinogens, informing prevention and treatment strategies (Bouvard et al., 2009). Management approaches, such as liver transplantation for small hepatocellular carcinomas in cirrhosis patients, demonstrate effectiveness against virus-related risks in immunocompromised groups (Mazzaferro et al., 1996).
Reading Guide
Where to Start
"Identification of Herpesvirus-Like DNA Sequences in AIDS-Sssociated Kaposi's Sarcoma" by Chang et al. (1994) because it provides the foundational discovery of KSHV sequences in over 90 percent of AIDS-KS tissues using representational difference analysis, establishing the viral link clearly.
Key Papers Explained
Chang et al. (1994) first identified herpesvirus-like DNA in AIDS-associated Kaposi's sarcoma, building the viral etiology foundation. Cesarman et al. (1995) extended this by detecting the same KSHV sequences in AIDS-related body-cavity-based lymphomas, confirming its role in distinct B-cell malignancies. Parkin (2006) quantified the global cancer burden from such infections, contextualizing incidence across regions. Bouvard et al. (2009) classified these biological agents as carcinogens, integrating prior findings into risk assessment frameworks.
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
Current research derives from established papers like those on KSHV in AIDS lymphomas (Cesarman et al., 1995) and infection burdens (Parkin, 2006), with no recent preprints or news available to indicate shifts.
Papers at a Glance
| # | Paper | Year | Venue | Citations | Open Access |
|---|---|---|---|---|---|
| 1 | Liver Transplantation for the Treatment of Small Hepatocellula... | 1996 | New England Journal of... | 7.0K | ✕ |
| 2 | Identification of Herpesvirus-Like DNA Sequences in AIDS-Sssoc... | 1994 | Science | 5.7K | ✕ |
| 3 | Detection and isolation of type C retrovirus particles from fr... | 1980 | Proceedings of the Nat... | 5.0K | ✓ |
| 4 | The 5th edition of the World Health Organization Classificatio... | 2022 | Leukemia | 3.3K | ✓ |
| 5 | Classification of papillomaviruses | 2004 | Virology | 3.2K | ✕ |
| 6 | National cancer institute sponsored study of classifications o... | 1982 | Cancer | 3.1K | ✓ |
| 7 | The global health burden of infection‐associated cancers in th... | 2006 | International Journal ... | 2.9K | ✓ |
| 8 | A review of human carcinogens—Part B: biological agents | 2009 | The Lancet Oncology | 2.9K | ✕ |
| 9 | Kaposi's Sarcoma–Associated Herpesvirus-Like DNA Sequences in ... | 1995 | New England Journal of... | 2.9K | ✓ |
| 10 | Human chronic myelogenous leukemia cell-line with positive Phi... | 1975 | Blood | 2.8K | ✕ |
Frequently Asked Questions
What DNA sequences were identified in AIDS-associated Kaposi's sarcoma?
Representational difference analysis isolated unique herpesvirus-like DNA sequences present in more than 90 percent of Kaposi's sarcoma tissues from AIDS patients (Chang et al., 1994). These sequences were absent in tissues from non-AIDS patients. The finding identified Kaposi's Sarcoma-associated herpesvirus (KSHV).
How does KSHV relate to AIDS-related lymphomas?
KSHV-like DNA sequences occur in an unusual subgroup of AIDS-related B-cell lymphomas known as body-cavity-based lymphomas (Cesarman et al., 1995). These sequences are not found in other lymphoid neoplasms studied. This strongly suggests a pathogenic role for the novel herpesvirus.
What is the global burden of infection-associated cancers?
Several infectious agents cause cancers in humans, with their fraction estimated across cancer types and regions worldwide in 2002 (Parkin, 2006). Methods included reviewing evidence for association strength. The estimates highlight the contribution of viruses to cancer incidence.
Which biological agents are classified as human carcinogens?
The International Agency for Research on Cancer reviewed human carcinogens including biological agents like viruses associated with cancers (Bouvard et al., 2009). This classification covers agents linked to malignancies such as those from EBV and KSHV. It supports targeted public health measures.
What treatment is effective for small hepatocellular carcinomas in cirrhosis?
Liver transplantation treats small, unresectable hepatocellular carcinomas in patients with cirrhosis (Mazzaferro et al., 1996). The approach shows effectiveness in this setting. It addresses virus-related risks in immunocompromised individuals.
Open Research Questions
- ? How do immunosuppression levels quantitatively influence EBV and KSHV reactivation rates leading to lymphoproliferative disorders?
- ? What specific mechanisms drive KSHV DNA integration and oncogenesis in AIDS-related body-cavity-based lymphomas?
- ? Which targeted therapies best mitigate post-transplant lymphoproliferative disease in recipients?
- ? How does antiretroviral therapy alter cancer incidence trends in HIV patients with viral co-infections?
Recent Trends
The field encompasses 64,855 works with growth data unavailable; foundational discoveries include KSHV identification in AIDS-Kaposi's sarcoma (Chang et al., 1994, 5670 citations) and its role in body-cavity lymphomas (Cesarman et al., 1995, 2855 citations), but no recent preprints or news signal changes.
Research Viral-associated cancers and disorders with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Viral-associated cancers and disorders with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers